EPTINEZUMAB (Vyepti®)

Clinical Indication

For the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Date of classification

January 2023

Grey

Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.